MedTrace Logo

Pulmonary Function After Hyperbaric Oxygen Therapy

NCT05088772 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 86

Last updated 2024-05-16

Study results available
· View outcomes & findings →

Summary

Patients receiving hyperbaric oxygen therapy (HBOT) for any indication at the Hyperbaric Medicine Unit (University Health Network, Toronto, ON, Canada) from 2016-2021 were recruited to this prospective cohort study. While receiving HBOT (at 2.0-2.4 ATA, with 1-3 "air breaks", with specific treatment details determined on a case-by-case basis and directed by the clinical team), enrolled patients underwent pulmonary function testing prior to HBOT treatment and serially after each 20 completed treatment cycles.

Conditions

  • Oxygen Toxicity

Interventions

DEVICE

Hyperbaric Oxygen Therapy

Hyperbaric Oxygen Therapy performed at 100% oxygen at 2.0-2.4 ATA, with 1-3 "air breaks", typically at 5 sessions per week, with limited variation depending on the treatment indication and patient/clinician preference.

Sponsors & Collaborators

  • University of Toronto

    lead OTHER

Principal Investigators

  • Rita Katznelson, MD FRCPC · Hyperbaric Medicine Unit, University Health Network, Toronto, ON, Canada

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2021-06-30
Completion
2022-10-31
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05088772 on ClinicalTrials.gov